RT Journal Article SR Electronic T1 Adjuvant-free mouse model of allergic asthma JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P4059 VO 44 IS Suppl 58 A1 Igor Shilovskiy A1 Mariya Prozorova A1 Alina Gaisina A1 Alexander Babakhin A1 Musa Khaitov YR 2014 UL http://erj.ersjournals.com/content/44/Suppl_58/P4059.abstract AB Background: Aluminum hydroxide (alum) is widely used for sensitization in mouse models of allergic asthma (MMA). The purpose of this study was to develop a phenotype of allergic airway inflammation in adjuvant-free MMA.Methods: BALB/c mice were sensitized according to two protocols. "Adjuvant protocol" (AP) consisted of three i.p. injections of 20 μg ovalbumin (OVA) with 2 mg of alum/mouse on days 0, 14 and 28 followed by five intranasal applications (INA) with 50 μl OVA (10 mg/ml) on days 41-45. "Adjuvant-free protocol" (AFP) included by three s.c. injections of the same OVA dose followed by INA with OVA at the same manner. 24 hours after the last INA airway hyperresponsiveness (AHR) to methacholine was measured by plethysmography. 48 hours after the last INA bronchoalveolar lavage (BAL) was performed for differential cell counts and lungs were removed for histological examination. OVA-specific serum IgE-, IgG1- and IgG2a- antibodies were detected by ELISA.Results: OVA-specific IgE production in AFP group was 1.6 fold higher than that of AP group. OVA-specific IgG2a level in AFP group was 3 times lower than that of AP group while levels of anti-OVA IgG1 were similar in both groups. AHR in AP and AFP groups was higher than that of normal mice but did not differ from each other. Both AP and AFP groups have an equal amount of inflammatory cells in BAL while lung histology picture (perivascular and peribronchial inflammation) was more expressive in AFP group.Conclusion: "Adjuvant-free protocol" generates an experimental asthma phenotype similar to that of "adjuvant protocol" which is widely used in the literature. The adjuvant-free MMA can be a relevant model for testing of new approaches in treatment or prevention of bronchial asthma.